Canaccord Genuity analyst John Young CFA maintained a Buy rating on Pulmonx yesterday and set a price target of $6.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
John Young CFA has given his Buy rating due to a combination of factors that suggest potential for Pulmonx’s stock. Despite recent challenges, the company reported Q3/25 revenue that met expectations and showed a slight year-over-year increase. The return of the former CEO and CFO, who are experienced and familiar with the business, is seen as a positive step towards addressing existing issues.
Furthermore, Pulmonx has a strong product and solid gross margins, which provide a foundation for future growth. The management’s commitment to sustainable, profitable growth and cost-saving initiatives is expected to extend the company’s cash runway. Although there are uncertainties regarding the timing and extent of the turnaround, the current valuation and management’s strategic focus make the stock an attractive investment opportunity.
According to TipRanks, Young CFA is an analyst with an average return of -1.7% and a 46.15% success rate. Young CFA covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, Staar Surgical, and Pulmonx.
In another report released yesterday, Lake Street also reiterated a Buy rating on the stock with a $4.00 price target.